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438Objective: Criteria for the growing teratoma syndrome in patients with primary mediastinal nonseminomatous
germ cell tumors have not been well established according to current practice.
Methods: An institutional database identified 188 patients who underwent postchemotherapy surgery for
primary mediastinal nonseminomatous germ cell tumors from 1981 to 2009. We reviewed the subset of patients
who underwent urgent surgery for tumor growth resulting in cardiopulmonary deterioration secondary to medi-
astinal compression precluding safe completion of 4 cisplatin-based chemotherapy cycles with rapidly declining
serum tumor markers.
Results: Five men (2.6%) with an average age of 25.8 years were identified. All patients initially presented with
a large symptomatic anterior mediastinal mass and elevated serum tumor markers. Patients received an average
of 2.4 chemotherapy cycles of a scheduled 4 courses before cardiopulmonary deterioration. Pathology of the
resected specimens demonstrated mature teratoma in all patients; however, it was admixed in 4 patients with
foci of immaturity (n ¼ 1), malignant transformation of teratoma to sarcoma (n ¼ 2), and nonseminomatous
germ cell tumor (n¼ 2). There was 1 operative death. Three of the 4 operative survivors subsequently completed
a total of 4 cycles of chemotherapy after recovery. Two patients are alive and well after an average of 14 years.
Two patients died of metastatic disease.
Conclusions: The growing teratoma syndrome should be defined not only as a growing mediastinal mass but
also with secondary cardiopulmonary deterioration precluding safe completion of planned chemotherapy in
the presence of declining serum tumor markers. Prompt recognition of this syndrome, discontinuation of che-
motherapy, and surgical intervention can result in cure. (J Thorac Cardiovasc Surg 2012;144:438-43)Nonseminomatous germ cell tumors frequently demonstrate
mixed histology. Common to all nonseminomatous germ
cell tumors are malignant elements that are sensitive to
cisplatin-based chemotherapy, including yolk sac carcinoma,
embryonal carcinoma, or choriocarcinoma, in order of
frequency. An admixture of varying proportions usually is
alsopresentwith elements that are not sensitive to chemother-
apy, including mature teratoma, immature teratoma, or, on
occasion, frankmalignant degeneration of teratoma into non-
germ cell cancers, such as sarcoma. The term ‘‘growing tera-
toma syndrome’’ (GTS) was first coined by Logothetis and
colleagues,1 reporting on patients with nonseminomatous
testicular cancer and growing retroperitoneal or lung massese Cardiothoracic Division,a Department of Surgery, Melvin and Bren Simon
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The Journal of Thoracic and Cardiovascular Surgduring observation after chemotherapy, and included the fol-
lowing criteria: normalization of previously elevated serum
tumormarkers, ‘‘paradoxical’’ increase in tumor size, and ab-
sence of any pathologic component other than mature tera-
toma in the surgical specimen.1 Since this definition in
1982, the treatment paradigm for nonseminomatous germ
cell tumors with cisplatin-based chemotherapy followed by
surgical resection of residual disease as a planned approach
in select patients has evolved and is considered one of the
most successful models of multimodality cancer therapy.
It has been well established that primary mediastinal non-
seminomatous germ cell tumors (PMNSGCT), although his-
tologically identical to their more common testicular
counterparts, have a distinctly inferior overall prognosis
and therefore have been designated as ‘‘poor risk’’ nonsemi-
nomatous germ cell tumors along with other subsets of tes-
ticular nonseminomatous germ cell tumors.2 Although
metastatic testicular nonseminomatous germ cell tumors
have an overall 5-year survival exceeding 80% with
cisplatin-based chemotherapy, their mediastinal counter-
parts demonstrate a more aggressive biology with 5-year
survivals averaging between 40% and 50%.3,4 Factors
that contribute to inferior survival include an overall
poorer response to chemotherapy and higher incidence of
degenerative nongerm cell cancer pathology in theery c August 2012
Abbreviations and Acronyms
AFP ¼ alpha-fetoprotein
BEP ¼ bleomycin, etoposide, cisplatin
CT ¼ computed tomography
GTS ¼ growing teratoma syndrome
PMNSGCT ¼ primary mediastinal
nonseminomatous germ cell tumor
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response to second-line chemotherapy, surgical removal of
any residual disease after recovery from cisplatin-based che-
motherapy as a planned approach for PMNSGCT has been
advocated.5-7 In this study, we review our institutional
experience with the subset of patients with PMNSGCT
who demonstrated tumor growth during chemotherapy
despite a decrease in serum tumor marker levels (alpha-
fetoprotein [AFP] and human chorionic gonadotropin),
which resulted in cardiopulmonary deterioration
secondary to mediastinal compression precluding safe
completion of 4 cisplatin-based chemotherapy cycles, man-
dating urgent surgery.
MATERIAL AND METHODS
After obtaining formal institutional approval, a prospective database
search initially identified 188 patients who underwent surgery at the Mel-
vin and Bren Simon Cancer Center for PMNSGCT after cisplatin-based
chemotherapy from 1981 to 2009. Of these, a subset of 5 patients
(2.6%) demonstrated tumor growth during chemotherapy with a rapid de-
crease in serum tumor marker levels. This resulted in cardiopulmonary de-
terioration secondary to mediastinal compression precluding safe
completion of or recovery from 4 cisplatin-based chemotherapy cycles,
mandating urgent surgery. These 5 patients constitute the basis of this
study. Institutional records or records provided by referring facilities
were reviewed. Multiple demographic, pathologic, operative, and outcome
variables were recorded.8
RESULTS
All 5 patients were healthy men aged 20 to 33 years
(mean, 25.8 years). All patients presented at the time of di-
agnosis with a large symptomatic anterior mediastinal mass
and elevated AFP at an average of 9137 ng/mL (range, 791-
36,000 ng/mL), diagnostic of a PMNSGCT. Human cho-
rionic gonadotropin was elevated in 3 patients with
a mean of 206 mIU/mL (range, 8-350 mIU/mL). Computed
tomography (CT) evidence of metastatic disease (lung) was
present in 1 patient at the time of diagnosis, with the remain-
ing patients presenting with disease isolated to the medias-
tinum. The specifics of all cases are described next and in
Table 1. Prechemotherapy biopsies demonstrated mature
teratoma in only 2 patients despite elevated AFP, mature ter-
atoma, and foci of nonseminomatous germ cell tumor in 2
patients and 1 patient with immature teratoma and foci of
nonseminomatous germ cell tumor. Patients received an av-
erage of 2.4 cycles (range, 1-3) of cisplatin-basedThe Journal of Thoracic and Cachemotherapy before undergoing surgery. Three patients
had normalized serum tumor markers, and 2 patients
demonstrated rapid serum tumor marker decline before
surgery.
The details of our surgical approach have been de-
scribed.7,9 In brief, the effectiveness of cisplatin-based che-
motherapy for germ cell cancer usually results in extensive
tumor necrosis that is more marked around the periphery.
This finding usually allows a complete resection that mini-
mizes operative morbidity by preserving critical structures
that abut but are not densely adherent to or directly involved
with the residual mass, such as lung, great veins, phrenic
nerves, and occasionally cardiac chambers where the ‘‘peri-
cardial barrier’’ has been violated. In general, we believe an
aggressive but balanced dissection to remove all residual
disease while sparing critical structures with generous use
of frozen-section analysis is warranted. Choosing the surgi-
cal approach that provides optimal exposure of residual dis-
ease and surrounding structures is initially critical. A
bilateral anterior thoracotomy with transverse sternotomy
(also called the ‘‘clamshell’’ incision) is used for large mid-
line tumors with significant extension into the chest.
Finally, cardiopulmonary bypass capabilities are available
for cases with large or invasive-appearing tumors, such as
in the patients reported in this series. Four patients under-
went a surgery through a clamshell approach. One patient
required an initial median sternotomy and then a sequential
left lateral thoracotomy. All 5 patients underwent complete
surgical extirpation of the mediastinal mass with tumor-free
margins. The 2 patients who had not normalized but demon-
strated rapid serum tumor marker decline at the time of sur-
gery had normalized tumor markers by the time of hospital
discharge.
Surgical pathology of the mediastinal mass demonstrated
mature teratoma only and mature teratoma with focal im-
maturity in 1 patient each. Pathology was mixed in the other
3 patients with predominately mature teratoma and focal
yolk sac cancer (n ¼ 1), nongerm cell cancer (angiosar-
coma, n ¼ 1), and a combination of yolk sac and nongerm
cell cancer (angiosarcoma, n¼ 1). One patient died of respi-
ratory failure postoperatively. Three of the 4 surviving pa-
tients received cisplatin-based chemotherapy after
recovery to complete 4 cycles. All 4 surviving patients re-
covered good to excellent performance status. Two patients
are alive and well 13 and 15 years after initial surgery; how-
ever, both have required further metastasectomies during
follow-up. The other 2 patients died of metastatic nongerm
cell cancer after 20 and 26 months.
Patient 1
A 22-year-old man presented with dyspnea and left-sided
chest discomfort. CT demonstrated a large anterior medias-
tinal mass (23 cm in longest dimension) compressing the tra-
chea, heart, and great vessels with almost total obliteration ofrdiovascular Surgery c Volume 144, Number 2 439
TABLE 1. Prechemotherapy and postchemotherapy pathology, serum tumor markers at diagnosis, and status at last follow-up
Patient no. Pathology at diagnosis
AFP
(ng/mL)
hCG
(mIU/mL)
Cycles of
chemotherapy Surgical pathology Status
Length of
follow-up
1 Immature teratoma with
focal yolk sac and
embryonal carcinoma
5131 Normal 2 Mature teratoma with
focal immature teratoma
Alive and well
(3 metastasectomies)
15 y
2 Mature teratoma 791 350 3 Mature teratoma with focal
yolk sac cancer
Alive and well
(1 metastasectomy)
13 y
3 Mature teratoma with
focal yolk sac
carcinoma
961 Normal 3 Mature teratoma with focal
angiosarcoma and yolk sac
carcinoma
Died of disease 1.7 y
4 Mature teratoma with
focal yolk sac
carcinoma
2800 8 3 Mature teratoma with focal
angiosarcoma
Operative death 36 d
5 Mature teratoma 36,000 261 1 Mature teratoma Died of disease 2.2 y
AFP, Alpha-fetoprotein; hCG, human chorionic gonadotropin.
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Sthe left pleural space. An open biopsy at an outside hospital
was consistent with predominately immature teratoma and
a small focus of embryonal cell carcinoma.He received 2 cy-
cles of bleomycin, etoposide, cisplatin (BEP) chemotherapy,
but symptoms of further respiratory distress and upper-body
edema consistent with superior vena cava obstruction devel-
oped. Repeat CT revealed an increase in the size of the lesion
with further cardiopulmonary compression (Figure 1). Se-
rum AFP was rapidly declining. He was then referred to
the Melvin and Bren Simon Cancer Center for urgent sur-
gery, which was performed through a clamshell approach.
The mass was excised requiring en bloc pericardiectomy,
a small area of diaphragm, andwedge resection of the left up-
per lobe and left phrenic nerve. Final pathology revealedFIGURE 1. Preoperative axial CT of patient 1 demonstrating a large het-
erogeneous anterior mediastinal mass with cardiac/great vessel displace-
ment and compression. The left pleural space is also obliterated. A
leftward clamshell approach provided adequate exposure to the anterior
mediastinum and pleural space for surgical removal.
440 The Journal of Thoracic and Cardiovascular Surgmature teratomawith foci of immaturity. He received 2 addi-
tional cycles of cisplatin-based chemotherapy after recovery.
Serum tumor marker levels remained normal; however, 2
new left-sided pulmonary nodules were identified on CT
scan after 3 years of follow-up. Both nodules were excised
and pathologically demonstrated mature teratoma only.
Three years after the second operation, posterior flank pain
developed in the patient, with CT revealing a mass involving
the chest wall in the left posterior costophrenic sulcus asso-
ciated with slight elevation of AFP. Fine-needle biopsy dem-
onstrated teratoma with foci of high-grade leiomyosarcoma
for which the patient underwent wide chest wall resection
and reconstruction. Seven years later, 13 years after the ini-
tial operation, another symptomatic recurrence with
a high-grade sarcoma involving a lower thoracic vertebral
body developed in the patient, for which he underwent verte-
brectomy. Thefindings of sarcoma in the chestwall and spine
represented malignant transformation of teratoma. At 15
years after the initial operation, the patient shows no
evidence of disease.Patient 2
A 30-year-old man presented with a cough, left-sided
chest discomfort, and progressive shortness of breath. CT
demonstrated a large anterior mediastinal mass (15 cm in
longest direction) obliterating two thirds of the left pleural
space with compression of the heart and great vessels along
with 2 pulmonary nodules suspicious for metastatic disease.
Fine-needle aspiration biopsy at an outside hospital demon-
strated only mature teratoma; however, significant elevation
of serum tumor markers indicated a malignant nonsemi-
nomatous component. After completion of the third cycle
of BEP chemotherapy, repeat imaging demonstrated an in-
crease in the mediastinal mass and serum tumor markers
had normalized. His shortness of breath was occurring
with minimal activity, and he was referred to the Melvin
and Bren Simon Cancer Center for surgical therapy beforeery c August 2012
FIGURE 2. Preoperative coronal CT of patient 5 demonstrating a large
heterogeneous anterior mediastinal mass with cardiac/great vessel dis-
placement and compression. The left pleural space is also obliterated. Be-
cause of significant inferior extension, surgical removal required an initial
sternotomy and sequential left thoracotomy.
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surgery, where excision requiring en bloc pericardiectomy
via a clamshell approach was performed. No pulmonary
resection was required to remove the mediastinal mass;
however, both lung nodules were removed separately. Final
pathology of the mediastinal mass revealedmature teratoma
with a focus of yolk sac carcinoma. The pulmonary nodules
pathologically demonstrated only mature teratoma. He re-
ceived 2 additional cycles of cisplatin-based chemotherapy
after recovery. One year after initial surgery, a symptomatic
recurrence involving a lower thoracic vertebra developed,
and he underwent vertebrectomy with pathology revealing
mature teratoma. At 13 years after the initial operation,
the patient shows no evidence of disease.
Patient 3
A 33-year-old man presented with symptoms of right
shoulder pain, dyspnea, and dysphagia. CT demonstrated
a large (15 cm in longest direction) anterior mediastinal
mass with compression of the heart, great vessels, and
trachea. Fine-needle aspiration biopsy at an outside hospital
confirmed the diagnosis of mature teratoma with foci of
yolk sac carcinoma. AFP was significantly elevated. After
completing the third round of BEP chemotherapy, the
patient experienced acute respiratory decompensation, stri-
dor, and symptoms of superior vena cava obstruction.
Repeat CT revealed a notable increase in the size of the
mass with almost complete tracheal occlusion from extrin-
sic compression. Serum tumor markers had normalized. He
was referred to the Melvin and Bren Simon Cancer Center
for urgent surgery. The mass was excised including en bloc
pericardiectomy, resection of the right phrenic nerve and
left innominate vein, and right upper and middle lobecto-
mies through a clamshell approach. Final pathology re-
vealed mature teratoma with foci of angiosarcoma and
yolk sac carcinoma. Widespread angiosarcoma metastases
developed in the patient, and he died 20 months after
surgery.
Patient 4
A 23-year-old presented with symptoms of dyspnea,
right-sided chest pain, and cough. CT demonstrated a large
(15 cm in longest direction) anterior mediastinal mass with
compression of the heart, great vessels, and almost total
obliteration of the right pleural space. Open biopsy at an
outside hospital showed mature teratoma with foci of yolk
sac carcinoma. After completing the third round of BEP
chemotherapy, the patient’s shortness of breath significantly
worsened with repeat CT demonstrating an increase in
tumor dimensions and further mediastinal compression.
Serum tumor markers were normalizing appropriately.
He was referred to the Melvin and Bren Simon Cancer
Center for urgent surgery, which required en bloc extrapleu-
ral right pneumonectomy for extensive lung and hilarThe Journal of Thoracic and Cainvolvement, and resection of the right phrenic nerve and
pericardium through a clamshell approach. Final pathology
revealed mainly mature teratoma with foci of angiosar-
coma. On the fourth postoperative day, the patient
manifested respiratory failure secondary to ‘‘postpneumo-
nectomy pulmonary edema,’’ and he died on postoperative
day 36.Patient 5
A 20-year-old presented with left shoulder pain and dysp-
nea. CT demonstrated a large (26 cm in longest dimension)
anterior mediastinal mass compressing the heart, great ves-
sels, and complete obliteration of the left pleural space with
inferior displacement of the diaphragm. Fine-needle biopsy
demonstrated only mature teratoma; however, serum tumor
markers were significantly elevated, diagnostic of
PMNSGCT. After completing the first BEP cycle, respira-
tory decompensation developed in the patient. Hewas trans-
ferred to the Melvin and Bren Simon Cancer Center with
CT showing an increase in tumor size and rapidly declining
serum tumor markers (Figure 2). The patient required intu-
bation shortly after transfer and underwent emergency sur-
gical resection of the mediastinal mass requiring en bloc left
upper lobectomy, resection of the left phrenic nerve, and
subtotal pericardiectomy. It was thought that a clamshell
approach would not provide adequate inferior exposure;
therefore, initial dissectionwas performed through amedian
sternotomy followed by a separate left posterolateral thora-
cotomy to complete the resection. Final pathology again re-
vealed only mature teratoma. The patient received the
remaining 3 cycles of cisplatin-based chemotherapy afterrdiovascular Surgery c Volume 144, Number 2 441
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sarcoma 26 months after surgery.
DISCUSSION
Given the ‘‘poor risk’’ designation of PMNSGCT, we
have maintained a policy of surgically removing any resid-
ual disease as a planned approach 4 to 6 weeks after com-
pleting 4 cycles of cisplatin-based chemotherapy, which
allows adequate functional and hematologic recovery be-
fore a major thoracic surgical procedure. Pathologic analy-
sis of 158 patients with PMNSGCTundergoing surgery after
chemotherapy at the Melvin and Bren Simon Cancer Center
revealed complete tumor necrosis in 25% and teratoma in
33%.9 The remaining 41% of patients pathologically dem-
onstrated elements of malignancy in the form of persistent
germ cell or non–germ cell cancer, with themajority of these
patients also having mixed pathology, including teratoma in
the surgical specimen. Theoretically therefore, if patients
with PMNSGCT were observed after completing chemo-
therapy, only a small fraction would demonstrate a stable re-
sidual mediastinal mass, with the majority developing
interval growth with normalized serum tumor markers (ma-
ture teratoma, immature teratoma, or nongerm cell cancer)
or interval growth with increasing serum tumor markers
(nonseminomatous germ cell cancer). Unfortunately, there
is no role for postchemotherapy positron emission tomogra-
phy scanning to determine the need for removal of a residual
mass, because teratoma does not demonstrate hypermeta-
bolic activity. Positron emission tomography also lacks
the sensitivity to identify microscopic foci of persistent non-
seminomatous germ cell or nongerm cell cancer.
The majority of PMNSGCTs occur in young adult men.
Most patients present symptomatically with chest pain,
cough, superior vena cava syndrome, or shortness of breath
secondary to a rapidly growing anterior mediastinal mass.
CT usually demonstrates a large heterogeneous mass with
occasional evidence of necrosis and hemorrhage. Associ-
ated pericardial and pleural effusions are also common, con-
tributing to the symptoms, but typically not malignant in
nature. Because of the sensitivity of nonseminomatous
germ cell cancer to cisplatin-based chemotherapy, there is
normally a significant decrease in the size of the mediastinal
neoplasm, decrease in serum tumor marker levels, and im-
provement in the patient’s respiratory status after chemo-
therapy is initiated. Because PMNSGCTs typically
demonstrate mixed histology, the response to chemotherapy
is proportional to the amount of chemosensitive pathology
within the individual neoplasm. For unusual patients with
significant amounts of pathology contained in the primary
neoplasm, which are not sensitive to chemotherapy, ‘‘para-
doxical’’ growth with decreasing serum tumor markers may
occur during chemotherapy. Pathology in PMNSGCT that is
not sensitive to chemotherapy and typically does not pro-
duce serum tumor markers would include not only mature442 The Journal of Thoracic and Cardiovascular Surgteratoma but also immature teratoma and degenerative
non–germ cell cancer. Although biopsy is not necessary to
establish a diagnosis of PMNSGCT, the finding that all pa-
tients in our GTS series pathologically demonstrated mature
teratoma or predominately mature teratoma with foci of
other mixed histology in prechemotherapy biopsy supports
this concept. In patients with large symptomatic neoplasms
at the time of presentation, only a small amount of tumor
growth may lead to cardiopulmonary deterioration. The
5 patients in this current series presented with large
anterior-based neoplasms extending into the pleural space
compressing the heart, great vessels, lung, or trachea. ‘‘Par-
adoxical’’ growth during chemotherapy resulted in cardio-
pulmonary deterioration and precluded safe administration
and recovery from 4 planned cisplatin-based chemotherapy
cycles. The large size of these neoplasms was underscored
by the surgical approach, clamshell or combined sternot-
omy/thoracotomy, required for removal.
In 1997, Afifi and coworkers10 reported a patient with
PMNSGCTwho met the original GTS criteria. Two months
after the patient received 4 cycles of cisplatin-based chemo-
therapy, cardiorespiratory deterioration secondary to tumor
growth developed, and the patient underwent urgent
surgery. Pathologic analysis of the mediastinal mass re-
vealed mature teratoma only. The patient was alive and
well after 2 years of follow-up. Other case reports of GTS
in patients with PMNSGCT have found predominately ma-
ture teratoma with a mixed postchemotherapy pathology,
challenging the concept that pathologic analysis of the
growing mass needs to demonstrate mature teratoma
only.11-14 Of note, only one of these more recent reports
described a patient with PMNSGCT who required urgent
surgery for cardiopulmonary deterioration before
completion of planned chemotherapy.14 Long-term fol-
low-up information was not available in this report. Pathol-
ogy of the growing mass included in this present GTS series
was mature teratoma in only 1 patient, with the other 4
patients demonstrating predominately teratoma with focal
elements of immature teratoma, nonseminomatous germ
cell, or nongerm cell cancer.
The combination ofBEPhas historically been the standard
chemotherapy for ‘‘poor risk’’ nonseminomatous germ cell
tumors, including PMNSGCT. A randomized trial compar-
ing BEP with etoposide, ifosfamide, and cisplatin for
‘‘poor risk’’ nonseminomatous germ cell tumors, including
PMNSGCT, demonstrated statistically equivalent survival.15
To eliminate the possibility of bleomycin-induced pulmo-
nary toxicity before a major thoracic surgical procedure,
we have used etoposide, ifosfamide, and cisplatin combina-
tion chemotherapy for patients with PMNSGCT over the
past 10 years. Since initiating this change, there has been
a significant reduction in postoperative respiratory failure
after major thoracic surgery at the Melvin and Bren Simon
Cancer Center. The potential for pulmonary complicationsery c August 2012
Kesler et al General Thoracic Surgeryis demonstrated by the single death in our series secondary to
respiratory failure in an otherwise young healthy man who
required urgent pneumonectomy immediately after receiv-
ing 3 courses of BEP chemotherapy.G
T
SCONCLUSIONS
GTS needs to be redefined for PMNSGCTon the basis of
a current treatment strategy. GTS should include a small
subset of patients with a growing mediastinal mass resulting
in symptomatic compression of the great vessels/heart/lungs
and decreasing serum tumor markers before or immediately
after the fourth cycle of cisplatin-based chemotherapy, pre-
cluding safe completion and recovery from chemotherapy
before surgery. In our series, symptomatic compression
ranged from shortness of breath with any activity to frank
cardiovascular collapse requiring intubation. Moreover, al-
though mature teratoma is the predominate pathology of
this subset, pathology is frequently mixed with foci of im-
mature teratoma, germ cell, or non–germ cell cancer. Prac-
titioners should have awareness for early recognition of this
syndrome. Discontinuation of chemotherapy and referral
for surgical therapy to prevent further cardiopulmonary de-
terioration are important. The surgical management of GTS
is challenging. Despite the massive size of these neoplasms,
resection with tumor-free margins can be accomplished.
Completion of planned chemotherapy after recovery is rec-
ommended. Long-term survival is possible; however, care-
ful surveillance is needed because early detection and
resection of recurrent disease can still be curative.The Journal of Thoracic and CaReferences
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